In-vivo metabolism of VLDL-apolipoprotein-B, -CIII and -E in normolipidemic subjects

Nutrition, Metabolism and Cardiovascular Diseases

Volumn 16, Issue 3, 2006, Pages 215-221

  Dinkel, Regina E ^a   Barrett, P Hugh R ^b   Demant, Thomas ^a,d   Parhofer, Klaus G ^a,c  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^c UNIVERSITY OF MUNICH   (Germany)

^d Inst Labormedizin   (Germany)

Author keywords

Lipoprotein metabolism; Multicompartmental modeling; Stable isotope tracer

Indexed keywords

EID: 33646018006     PISSN: 09394753     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.numecd.2005.06.004     Document Type: Article

References (23)

1. Ribalta J, Vallve JC, Girona J, Masana L. Apolipoprotein and apolipoprotein receptor genes, blood lipids and disease. Curr Opin Clin Nutr Metab Care 2003;6:177-87.
2. Shachter NS. Apolipoproteins C-I and C-III as important modulators of lipoprotein metabolism. Curr Opin Lipidol 2001;12:297-304.
3. Curtiss L, Boisvert WA. Apolipoprotein E and atherosclerosis. Curr Opin Lipidol 2000;11:243-51.
4. Batal R, Tremblay M, Barrett PHR, Jaques H, Fredenrich A, Mamer O, et al. Plasma kinetics of apoCIII and apoE in normolipemic and hypertriglyceridemic subjects. J Lipid Res 2000;41:706-18.
5. Bukberg PR, Le NA, Ginsberg HN, Gibson JC, Rubinstein A, Brown WV. Evidence for non-equilibrating pools of apolipoprotein C-III in plasma lipoproteins. J Lipid Res 1985;26:1047-57.
6. 2, and VLDL-apolipoprotein B in normal and hyperlipoproteinemic subjects. J Lipid Res 1981;22:1235-46.
7. Gregg RE, Zech LA, Schaefer EJ, Brewer Jr HB. Apolipoprotein E metabolism in normolipoproteinemic human subjects. J Lipid Res 1984;25:1167-76.
8. Gregg RE, Brewer Jr HB. The role of apolipoprotein E and lipoprotein receptors in modulating the in vivo metabolism of apolipoprotein B-containing lipoproteins in human plasma. Clin Chem 1988;32:B28-32.
9. Malmendier CL, Lontie JF, Grutman GA, Delcroix C. Metabolism of apolipoprotein C-III in normolipemic human subjects. Atherosclerosis 1988;69:51-9.
10. Millar JS, Lichtenstein AH, Dolnikowski GG, Ordovas JM, Schaefer EJ. Proposal of a multicompartmental model for use in the study of apolipoprotein E metabolism. Metabolism 1998;47:922-8.
11. Patterson BW, Hachey DL, Cook GL, Amann JM, Klein PD. Incorporation of a stable isotopically labeled amino acid into multiple human apolipoproteins. J Lipid Res 1991;32:1063-72.
12. Cohn JS, Batal R, Tremblay M, Jaques H, Veilleux L, Rodriguez H, et al. Plasma turnover of HDL apoC-I, apoC-III, and apoE in humans: in vivo evidence for a link between HDL apoC-III and apoA-I. J Lipid Res 2003;44:1976-83.
13. Cohn JS, Tremblay M, Batal R, Jaques H, Rodriguez C, Steiner G, et al. Increased apoC-III production is a characteristic feature of patients with hypertriglyceridemia. Atherosclerosis 2004;177:137-45.
14. Parhofer KG, Barrett PHR, Demant T, Schwandt P. Acute effects of LDL-apheresis on metabolic parameters of apolipoprotein B. J Lipid Res 2000;41:1596-603.
15. Parhofer KG, Barrett PHR, Bier DM, Schonfeld G. Lipoproteins containing the truncated apolipoprotein, apo B-89 are cleared from human plasma more rapidly than apo B-100 containing lipoproteins. J Clin Invest 1992;89:1931-7.
16. Parhofer KG, Barrett PHR, Bier DM, Schonfeld G. Determination of kinetic parameters of apolipoprotein B metabolism using amino acids labeled with stable isotopes. J Lipid Res 1991;32:1311-23.
17. Lowry OH, Rosenbrough NJ, Farr AL, Randall RJ. Protein measurement with the Polin phenol reagent. J Biol Chem 1951;193:265-75.
18. Matthews DE, Ben-Galin E, Bier DM. Determination of stable isotopic enrichment in individual plasma amino acids by chemical ionization mass spectrometry. Anal Chem 1979;51:80-4.
19. Demant T, Packard CJ, Demmelmair H, Stewart P, Bedyenk A, Bedford D, et al. Sensitive methods to study human apolipoprotein B metabolism using stable isotope-labeled amino acids. Am J Physiol 1996;270:E1022-36.
20. Cobelli C, Toffolo G, Foster DM. Tracer-to-tracee ratio for analysis of stable isotope tracer date: link with radioactive kinetic formalism. Am J Physiol 1992;262:E968-75.
21. Welty FK, Lichtenstein AH, Barrett PHR, Dolnikowski GG, Ordovas JM, Schwafer EJ. Production of apolipoprotein B-67 in apolipoprotein B-67/B-100 heterozygotes: technical problems associated with leucine contamination in stable isotope studies. J Lipid Res 1997;38:1535-43.
22. Marsh JB, Welty FK, Lichtenstein AH, Lamon-Fava S, Sschaefer EJ. Apolipoprotein B metabolism in humans: studies with stable isotope-labeled amino acid precursors. Atherosclerosis 2002;162:227-44.
23. Rensen PC, Jong MC, van Vark LC, Van der Boom H, Hendriks TJ, van Berkel TJ, et al. Apolipoprotein E is resistant to intracellular degradation in vitro and in vivo. Evidence for retroendocytosis. J Biol Chem 2000;257:8564-71.